Shares of DENTSPLY SIRONA Inc (NASDAQ:XRAY) ended Tuesday session in red amid volatile trading. The shares closed down -0.50 points or -0.81% at $61.20 with 266.01 million shares getting traded. Post opening the session at $61.64, the shares hit an intraday low of $60.87 and an intraday high of $61.66 and the price vacillated in this range throughout the day. The company has a market cap of $14.27 Billion and the numbers of outstanding shares have been calculated to be 233.01million shares.
DENTSPLY SIRONA Inc (XRAY) designs, develops, manufactures, and markets various consumable dental products for the professional dental market in the United States and internationally. The company provides dental consumable products, including dental anesthetics, prophylaxis paste, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride; and small equipment products comprising dental handpieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.
Shares of Orexigen Therapeutics, Inc. (NASDAQ:OREX) ended Tuesday session in red amid volatile trading. The shares closed down -0.12 points or -3.11% at $3.74 with 14.59 million shares getting traded. Post opening the session at $3.86, the shares hit an intraday low of $3.70 and an intraday high of $3.96 and the price vacillated in this range throughout the day. The company has a market cap of $53.72 million and the numbers of outstanding shares have been calculated to be 14.59 million shares.
Orexigen Therapeutics, Inc. (OREX) on Aug. 30, 2016 announced that Valeant Canada, a subsidiary of Valeant Pharmaceuticals International, Inc., or its affiliates, will commercialize Contrave® (naltrexone HCl / bupropion HCl extended release) in Canada. Under the terms of the agreement between Valeant and Orexigen’s wholly owned subsidiary Orexigen Therapeutics Ireland Ltd., Valeant will be responsible for obtaining Canadian regulatory approval and for all commercialization activity and expenses. Orexigen will supply Contrave tablets to Valeant Canada or its affiliates for an agreed transfer price and certain potential regulatory and sales milestone payments. Orexigen expects Valeant to file with Health Canada for regulatory approval by January 2017.
“Valeant Canada has a growing portfolio of innovative medicines addressing cardiometabolic disease, as well as strong regulatory and commercial capabilities, and we believe they are an ideal partner for Contrave in Canada,” said Mike Narachi, CEO of Orexigen. “Partnering with strong pharmaceutical companies outside the United States supports our global mission to improve the health and lives of patients struggling to lose weight and allows Orexigen to realize the global value of Contrave / Mysimba®.”
“Our agreement with Orexigen will bring long-term value to one of our key growth platforms,” said Richard Lajoie, Vice-President of the Pharma Business Unit at Valeant Canada. “This addition to our portfolio helps us to offer an even broader range of innovative treatments to physicians and weight management specialists for patients suffering from obesity.”